Cochrane COVID-19 Studienregister
NCT05043376Erstmals veröffentlicht: 2021 Sept 14Letzte Aktualisierung: 2021 Sept 14

A Randomized, Open-labelled, and Controlled Clinical Trial to Study the Adjuvant Treatment Benefits of Probiotic Streptococcus Salivarius K12 to Prevent/Reduce Lung Inflammation in Mild-to-moderate Hospitalised Patients With COVID-19

  1. Studientyp
  2. Interventional
  1. Studienziel
  2. Treatment and Management
  1. Studiendesign
  2. Parallel/Crossover
  1. Interventionszuordnung
  2. Randomised

Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Mild-to-moderate COVID-19

King Edward Medical University
Erstmals veröffentlicht (first received 2021 September 14) (
Eintrag in Studienregister
Keine Ergebnisse
This is a randomised, open-label and control clinical trial aimed to investigate the adjuvant treatment benefits of probiotic Streptococcus salivarius K12 in hospitalised mild-to-moderate patients with COVID-19 disease